Witjes - Figure 9
Intermediate-Risk Disease Recommendation
FIG. 9: Recommendations for intermediate-risk patients are again similar in both the AUA[1] and EAU[2] guidelines; they each advise one single postoperative instillation of chemotherapy. After that, they recommend an induction course of chemotherapy or immunotherapy, meaning already possible BCG, followed, for patients who do well after induction therapy without many side effects, by maintenance chemotherapy or maintenance BCG.
References
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer; unabridged version: American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. Linthicum, MD: American Urological Association; 2016 https://www.auanet.org/documents/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf Accessed August 3, 2017.
Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017;71:447−61 http://dx.doi.org/10.1016/j.eururo.2016.05.041
